We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

More pain

7 April 2005 By Robert Cyran

The drugs company’s forced withdrawal of Bextra worsens rival Merck s legal position over its closely related painkiller Vioxx. On the basis of the cost of settlements for other pulled drugs, Merck could be facing a final bill of at least $16bn.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)